Although SGLT2is are typically used in patients with type 2 diabetes and are not approved for those with type 1 diabetes in many countries, they have been used off-label as adjunctive therapy to insulin in some cases, raising concerns regarding an increased risk of SGLT2i-associated EDKA [7]. The gene discussed is INS; the disease is type 1 diabetes mellitus.